Cancer Chemotherapy Reviews Indexed in
EMBASE/Excerpta Medica
Monday, December 17, 2018 
ISSN: 2339-8728
Subscribers area
Home Editorial Board Journal Contents Subscriptions Contact Us Authors Instructions
<<< back |

Regorafenib in Advanced Colorectal Cancer

January-March 2017, Volume 12, Number 1
Pilar García-Alfonso, Andrés Muñoz-Martín, Montserrat Blanco-Codeisido and Aitana Calvo-Ferrándiz
Gregorio Marañon University General Hospital, Madrid, Spain

Regorafenib provides statistically significant improvements in terms of overall survival, progression-free survival, and disease control in pretreated patients with advanced metastatic colorectal cancer, as demonstrated in two placebo-controlled, randomized, phase III trials (CORRECT and CONCUR). Similar results were observed in two open-label, single-arm studies (REBECCA and CONSIGN). Several authors have suggested that not all the subgroups of patients could benefit from regorafenib, and thus that the benefit provided may not be clinically meaningful for these patients. This review aims to provide an analysis of the existing evidence in terms of efficacy and tolerability of regorafenib in different subpopulations according to clinical characteristics. The magnitude of the clinical benefits provided by regorafenib and whether there are poorer outcomes or not in certain subpopulations has also been explored.

Key words:
Antineoplastic agents. Colorectal cancer. Overall survival. Protein kinase inhibitor.
[Buy Article]
Mallorca, 310 - 08037 Barcelona - Spain
Phone: +34 93 207 59 20
Fax: +34 93 457 66 42
© Permanyer Publications | Made & Powered by IMMA PUIG | Privacy Policy - Legal notice